Format

Send to

Choose Destination
Expert Rev Respir Med. 2016 Jun;10(6):643-54. doi: 10.1586/17476348.2016.1166960. Epub 2016 Mar 31.

Assessment of treatment response in tuberculosis.

Author information

1
a Department of Medicine , Imperial College London , London , UK.
2
b Clinical Infectious Diseases Research Initiative, Institute of Infectious Diseases and Molecular Medicine and Department of Medicine , University of Cape Town , Observatory , South Africa.
3
c The Francis Crick Institute Mill Hill Laboratory , London , UK.

Abstract

Antibiotic treatment of tuberculosis has a duration of several months. There is significant variability of the host immune response and the pharmacokinetic-pharmacodynamic properties of Mycobacterium tuberculosis sub-populations at the site of disease. A limitation of sputum-based measures of treatment response may be sub-optimal detection and monitoring of Mycobacterium tuberculosis sub-populations. Potential biomarkers and surrogate endpoints should be benchmarked against hard clinical outcomes (failure/relapse/death) and may need tailoring to specific patient populations. Here, we assess the evidence supporting currently utilized and future potential host and pathogen-based models and biomarkers for monitoring treatment response in active and latent tuberculosis. Biomarkers for monitoring treatment response in extrapulmonary, pediatric and drug resistant tuberculosis are research priorities.

KEYWORDS:

Tuberculosis; biomarkers; humans; therapeutics; treatment outcome

PMID:
27030924
PMCID:
PMC4949330
DOI:
10.1586/17476348.2016.1166960
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center